Boosting immune cells after lung cancer chemoradiation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether a medicine called NKTR-255 can help restore and strengthen immune cells after standard chemoradiation for non-small cell lung cancer. The goal is to improve how well the body can fight the cancer after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and have non-small cell lung cancer confirmed by biopsy/pathology
- Plan to receive definitive (curative-intent) treatment, and sign consent before any study procedures
- Have no other active cancers elsewhere (with limited exceptions like low-risk prostate or skin cancers)
- Have good blood/organ health: liver tests and kidney function must be within allowed limits
- Be able to function fairly well (ECOG 0–2) and follow study visits and consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests adding natural killer (NK) cell therapy to standard chemo and immunotherapy before surgery for stage IB to IIIA non-small cell lung cancer that can be removed. It aims to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
This trial tests a personalized combination of radiation and immunotherapy for people with locally advanced non-small cell lung cancer that has a high level of a protein called PD-L1. It aims to improve treatment by tailoring the therapy to each patient's tumor.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.